Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Darzalex
(United States) [Available]Synonyms :
Daratumumab
Class :
Antineoplastics and Monoclonal Antibody
Brand Name :
Darzalex
(United States) [Available]Synonyms :
Daratumumab
Class :
Antineoplastics and Monoclonal Antibody
Dosage Forms & StrengthsÂ
Injectable solution for single-use vialÂ
100mg per 5ml -20mg/mlÂ
400mg per 20ml -20mg/mlÂ
Combination with lenalidomide or pomalidomide and dexamethasone for monotherapy (4-week course):
for weeks 1-8, a dose of 16 mg per kg was IV weekly, a total of 8 doses
for weeks 9-24, a dose of 16 mg per kg given IV for every two weeks a total of 8 doses 1st dose every two-week dosing schedule assigned till week 9
from week 25 onwards till disease progression, a dose of 16 mg per kg given IV every four weeks 1st dose every 4-week dosing schedule given till week 25
Combination with bortezomib, melphalan, and prednisone 6-week cycle:
for weeks 1-8, a dose of 16 mg per kg IV weekly, a total of 6 doses
for weeks 7-54, a dose of 16 mg per kg given IV every three weeks a total of 16 doses 1st dose every 3-week dosing schedule assigned till week 7
from week 55 onwards until disease progression, a dose of 16 mg per kg given IV every four weeks 1st dose every-4-week dosing schedule assigned till Week 55
Combination with bortezomib, thalidomide, and dexamethasone 4-week cycle:
for weeks 1-8, a dose of 16 mg per kg IV weekly, a total of 8 doses
for weeks 9-16, a dose of 16 mg per kg given IV for every two weeks a total of 4 doses 1st dose every 2-week dosing schedule assigned till week 9
Stop high dose chemotherapy and ASCT:
consolidation:
for weeks 1-8, a dose of 16 mg per kg is given IV for every two weeks 1st dose every 2-week dosing schedule is given at week one
Combination with bortezomib and dexamethasone 3-week cycle:
for weeks 1-9, a dose of 16 mg per kg IV weekly, a total of 9 doses
for weeks 10-24, a dose of 16 mg per kg given IV every three weeks a total of 5 doses 1st dose every-3-week dosing schedule given till week 10
from week 25 onwards until disease progression, a dose of 16 mg per kg IV every four weeks and 1st dose every-4-week dosing schedule given till week 25
Combination of carfilzomib and dexamethasone 4-week cycle:
for week one, a dose of 8 mg per kg IV on days 1 and 2, a total of 2 doses
for weeks 2-8, a dose of 16 mg per kg IV weekly, a total of 7 doses
for weeks 9-24, a dose of 16 mg/kg IV every two weeks, a total of 8 doses, and 1st dose every-2-week dosing schedule is given till Week 9
from week 25 onwards until disease progression, a dose of 16 mg per kg
every four weeks and 1st doses every-4-week dosing schedule till Week 25
may increase the risk of toxic effects when combined
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of severe and potentially fatal infections  
when both drugs are combined, there may be an increased risk of developing a disease from the vaccine   
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections  
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be reduced levels of white blood cell count  
when both drugs are combined, there may be reduced levels of white blood cell count  
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine  
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections  
when both drugs are combined, there may be an increased risk of severe life-threatening infections  
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections  
when both drugs are combined, there may be an increased risk of severe life-threatening infections
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be a decreased blood levels and effects of daratumumab  
when both drugs are combined, there may be an increased risk of kidney damage    
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk of kidney damage   
when both drugs are combined, there may be an increased risk or severity of adverse effects 
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
It may enhance the risk of adverse effects when combined with vitamins
daratumumab: it may increase the risk of methemoglobinemia with ambroxol
It may enhance the adverse effects when combined with sotrovimab
Actions and Spectrum:Â
Actions:Â
Daratumumab targets the CD38 protein on myeloma cells aiding the immune system in identifying and eliminating them.Â
Spectrum:Â
It is effective alone or with other treatments, but still ongoing studies need to explore its potential in earlier stages.Â
Frequency definedÂ
>10%Â
NauseaÂ
diarrheaÂ
VomitingÂ
LymphopeniaÂ
neutropeniaÂ
thrombocytopeniaÂ
AnemiaÂ
Infusion reactionÂ
Decreased appetiteÂ
Back painÂ
ArthralgiaÂ
Pain in extremityÂ
Musculoskeletal chest painÂ
1-10%Â
PneumoniaÂ
Herpes zoster reactivationÂ
BronchospasmÂ
DyspneaÂ
HypoxiaÂ
Blackbox warningÂ
Hepatitis B riskÂ
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy/Lactation:Â
Pregnancy warnings:Â
AU TGA pregnancy category: CÂ
US FDA pregnancy category: Not assignedÂ
Breastfeeding warnings:Â
The release of the drug into the breastmilk is unknownÂ
There is no data available for animal studiesÂ
Pregnancy Categories:Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimesterÂ
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant womenÂ
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant womenÂ
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefitsÂ
Category X: Drugs listed in this category outweigh risks over benefits Hence these categories of drugs need to be avoided by pregnant womenÂ
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
This drug treats multiple myeloma which inhibits the cell proliferation and apoptosis.Â
Pharmacodynamics:Â
The monoclonal antibody binds strongly to CD38 on myeloma cells resulting in cell death. It also triggers immunological responses involves phagocytosis and cytotoxicity.Â
Pharmacokinetics:Â
AbsorptionÂ
It undergoes rapid absorption.Â
DistributionÂ
It is widely distributed through the blood stream.Â
MetabolismÂ
Undergoes hepatic metabolism through the CYP3A enzymes.Â
Excretion and eliminationÂ
The drug is eliminated through renal clearance.Â
Administration:Â
It is administered through intravenously.Â
Patient information leafletÂ
Generic Name: daratumumabÂ
Pronunciation: da-ratu-moo-mabÂ
Why do we use daratumumab?Â
Daratumumab is used to treat multiple myeloma, a type of blood cancer. It targets the CD38 protein on myeloma cells, helping the immune system recognize and destroy them. It is used alone or in combination with other medications, especially in patients who have not responded well to previous treatments.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
